ETRANSAFE is a research project funded within the Innovative Medicines Initiative (IMI), which aims at developing integrated databases and computational tools (the eTRANSAFE ToxHub) that support the translational safety assessment of new drugs by using legacy data provided by the pharmaceutical companies that participate in the project. The project objectives include the development of databases containing preclinical and clinical data, computational systems for translational analysis including tools for data query, analysis and visualization, as well as computational models to explain and predict drug safety events.

Precision medicine and therapeutic development rely on a comprehensive understanding of genotype-phenotype relationships, yet this information remains fragmented across diverse sources. DISGENET, established over 15 years ago, addresses this challenge by systematically integrating gene-disease, variant-disease, and disease-disease associations from authoritative databases and the literature. This major upgrade expands coverage with chemical and pharmacological annotations and integrates biobank and clinical data. An advanced natural language processing (NLP) pipeline captures emerging evidence with full provenance and contextual details, key to streamlining data-driven insights. DISGENET supports diverse users through multiple tools, including an intuitive web interface, a REST API, an R package, a Cytoscape app, and an AI assistant for natural language queries. Quarterly updates ensure data currency, while a sustainable freemium model provides free academic access and supports ongoing development. DISGENET aims to accelerate data-driven discoveries and advance precision medicine and drug development. The platform is accessible at https://www.disgenet.com.